A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from the processing of allogeneic human somatic stem cells

Takao Hayakawa, Takashi Aoi, Akihiro Umezawa, Keiya Ozawa, Yoji Sato, Yoshiki Sawa, Akifumi Matsuyama, Shinya Yamanaka, Masayuki Yamato

研究成果: Article

3 引用 (Scopus)

抄録

As a series of endeavors to establish suitable measures for the sound development of regenerative medicine using human stem cell-based products, we studied scientific principles, concepts, and basic technical elements to ensure the quality and safety of therapeutic products derived from allogeneic human somatic stem cells, taking into consideration scientific and technological advances, ethics, regulatory rationale, and international trends in human stem cell-derived products. This led to the development of the Japanese official Notification No. 0907-3, “Guideline on Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Derived from the Processing of Allogeneic Human Somatic Stem Cells,” issued by Pharmaceuticals and Food Safety Bureau, Ministry of Health, Labour and Welfare of Japan, on September 7, 2012. The present paper describes the background information and development of our study and the resulting guidance. For products derived from allogeneic somatic stem cells, major points to consider include 1) history, the source, and derivation of starting cells; 2) donor screening/testing and donor eligibility, especially in relation to the presence of adventitious agents, potential occurrence of donor-derived diseases, and immunocompatibility; 3) clinical records of a donor; 4) multipotency and self-replication ability of allogeneic human somatic stem cells; 5) cell banking; 6) potential presence of viruses in the final product; 7) extensive characterization of the cells at critical stage(s) of manufacture; 8) robustness of the manufacturing process; 9) quality consistency of the products such as the final products and critical intermediate(s) if any; and 10) robust application and function of the final products in a cell environment different from where the original cells were localized and were performing their natural endogenous function. The ultimate goal of this guidance is to provide suitable medical opportunities as soon as possible to the patients with severe diseases that are difficult to treat with conventional modalities.

元の言語English
ページ(範囲)70-80
ページ数11
ジャーナルRegenerative Therapy
2
DOI
出版物ステータスPublished - 12-2015

Fingerprint

Equipment Safety
Adult Stem Cells
Stem cells
Drug products
Processing
Pharmaceutical Preparations
Tissue Donors
Stem Cells
Donor Selection
Histocompatibility
Regenerative Medicine
Food Safety
Food safety
Ethics
Japan
Viruses
History
Guidelines
Screening
Safety

All Science Journal Classification (ASJC) codes

  • Biomaterials
  • Biomedical Engineering
  • Developmental Biology

これを引用

Hayakawa, Takao ; Aoi, Takashi ; Umezawa, Akihiro ; Ozawa, Keiya ; Sato, Yoji ; Sawa, Yoshiki ; Matsuyama, Akifumi ; Yamanaka, Shinya ; Yamato, Masayuki. / A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from the processing of allogeneic human somatic stem cells. :: Regenerative Therapy. 2015 ; 巻 2. pp. 70-80.
@article{cf4bb4907ddf459b840e4c4cdcf7a7b7,
title = "A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from the processing of allogeneic human somatic stem cells",
abstract = "As a series of endeavors to establish suitable measures for the sound development of regenerative medicine using human stem cell-based products, we studied scientific principles, concepts, and basic technical elements to ensure the quality and safety of therapeutic products derived from allogeneic human somatic stem cells, taking into consideration scientific and technological advances, ethics, regulatory rationale, and international trends in human stem cell-derived products. This led to the development of the Japanese official Notification No. 0907-3, “Guideline on Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Derived from the Processing of Allogeneic Human Somatic Stem Cells,” issued by Pharmaceuticals and Food Safety Bureau, Ministry of Health, Labour and Welfare of Japan, on September 7, 2012. The present paper describes the background information and development of our study and the resulting guidance. For products derived from allogeneic somatic stem cells, major points to consider include 1) history, the source, and derivation of starting cells; 2) donor screening/testing and donor eligibility, especially in relation to the presence of adventitious agents, potential occurrence of donor-derived diseases, and immunocompatibility; 3) clinical records of a donor; 4) multipotency and self-replication ability of allogeneic human somatic stem cells; 5) cell banking; 6) potential presence of viruses in the final product; 7) extensive characterization of the cells at critical stage(s) of manufacture; 8) robustness of the manufacturing process; 9) quality consistency of the products such as the final products and critical intermediate(s) if any; and 10) robust application and function of the final products in a cell environment different from where the original cells were localized and were performing their natural endogenous function. The ultimate goal of this guidance is to provide suitable medical opportunities as soon as possible to the patients with severe diseases that are difficult to treat with conventional modalities.",
author = "Takao Hayakawa and Takashi Aoi and Akihiro Umezawa and Keiya Ozawa and Yoji Sato and Yoshiki Sawa and Akifumi Matsuyama and Shinya Yamanaka and Masayuki Yamato",
year = "2015",
month = "12",
doi = "10.1016/j.reth.2015.05.001",
language = "English",
volume = "2",
pages = "70--80",
journal = "Regenerative Therapy",
issn = "2352-3204",
publisher = "Japanese Society of Regenerative Medicine",

}

A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from the processing of allogeneic human somatic stem cells. / Hayakawa, Takao; Aoi, Takashi; Umezawa, Akihiro; Ozawa, Keiya; Sato, Yoji; Sawa, Yoshiki; Matsuyama, Akifumi; Yamanaka, Shinya; Yamato, Masayuki.

:: Regenerative Therapy, 巻 2, 12.2015, p. 70-80.

研究成果: Article

TY - JOUR

T1 - A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from the processing of allogeneic human somatic stem cells

AU - Hayakawa, Takao

AU - Aoi, Takashi

AU - Umezawa, Akihiro

AU - Ozawa, Keiya

AU - Sato, Yoji

AU - Sawa, Yoshiki

AU - Matsuyama, Akifumi

AU - Yamanaka, Shinya

AU - Yamato, Masayuki

PY - 2015/12

Y1 - 2015/12

N2 - As a series of endeavors to establish suitable measures for the sound development of regenerative medicine using human stem cell-based products, we studied scientific principles, concepts, and basic technical elements to ensure the quality and safety of therapeutic products derived from allogeneic human somatic stem cells, taking into consideration scientific and technological advances, ethics, regulatory rationale, and international trends in human stem cell-derived products. This led to the development of the Japanese official Notification No. 0907-3, “Guideline on Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Derived from the Processing of Allogeneic Human Somatic Stem Cells,” issued by Pharmaceuticals and Food Safety Bureau, Ministry of Health, Labour and Welfare of Japan, on September 7, 2012. The present paper describes the background information and development of our study and the resulting guidance. For products derived from allogeneic somatic stem cells, major points to consider include 1) history, the source, and derivation of starting cells; 2) donor screening/testing and donor eligibility, especially in relation to the presence of adventitious agents, potential occurrence of donor-derived diseases, and immunocompatibility; 3) clinical records of a donor; 4) multipotency and self-replication ability of allogeneic human somatic stem cells; 5) cell banking; 6) potential presence of viruses in the final product; 7) extensive characterization of the cells at critical stage(s) of manufacture; 8) robustness of the manufacturing process; 9) quality consistency of the products such as the final products and critical intermediate(s) if any; and 10) robust application and function of the final products in a cell environment different from where the original cells were localized and were performing their natural endogenous function. The ultimate goal of this guidance is to provide suitable medical opportunities as soon as possible to the patients with severe diseases that are difficult to treat with conventional modalities.

AB - As a series of endeavors to establish suitable measures for the sound development of regenerative medicine using human stem cell-based products, we studied scientific principles, concepts, and basic technical elements to ensure the quality and safety of therapeutic products derived from allogeneic human somatic stem cells, taking into consideration scientific and technological advances, ethics, regulatory rationale, and international trends in human stem cell-derived products. This led to the development of the Japanese official Notification No. 0907-3, “Guideline on Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Derived from the Processing of Allogeneic Human Somatic Stem Cells,” issued by Pharmaceuticals and Food Safety Bureau, Ministry of Health, Labour and Welfare of Japan, on September 7, 2012. The present paper describes the background information and development of our study and the resulting guidance. For products derived from allogeneic somatic stem cells, major points to consider include 1) history, the source, and derivation of starting cells; 2) donor screening/testing and donor eligibility, especially in relation to the presence of adventitious agents, potential occurrence of donor-derived diseases, and immunocompatibility; 3) clinical records of a donor; 4) multipotency and self-replication ability of allogeneic human somatic stem cells; 5) cell banking; 6) potential presence of viruses in the final product; 7) extensive characterization of the cells at critical stage(s) of manufacture; 8) robustness of the manufacturing process; 9) quality consistency of the products such as the final products and critical intermediate(s) if any; and 10) robust application and function of the final products in a cell environment different from where the original cells were localized and were performing their natural endogenous function. The ultimate goal of this guidance is to provide suitable medical opportunities as soon as possible to the patients with severe diseases that are difficult to treat with conventional modalities.

UR - http://www.scopus.com/inward/record.url?scp=85045291515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045291515&partnerID=8YFLogxK

U2 - 10.1016/j.reth.2015.05.001

DO - 10.1016/j.reth.2015.05.001

M3 - Article

AN - SCOPUS:85045291515

VL - 2

SP - 70

EP - 80

JO - Regenerative Therapy

JF - Regenerative Therapy

SN - 2352-3204

ER -